Infinity Pharma And Bristol-Myers Squibb Expand Clinical Collaboration Evaluating IPI-549 In Combination With Opdivo (Nivolumab) Post author:Sam Post published:September 24, 2017 Post category:BioPharma Life Sciences Jobs … Source: BioSpace You Might Also Like Nestle Emerges as the Frontrunner for Merck KGaA's $5B Consumer Health Biz January 9, 2018 Janssen R&D Release: Data At ASCO Show Consistent Progression-Free Survival Benefit In Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Patients Treated With Ibrutinib, Including Those With High-Risk Disease, With Up To Four Years Of Follow-Up June 4, 2017 New Jersey Startup Launches With Clinical Assets From Big Name Biotechs August 21, 2017
Janssen R&D Release: Data At ASCO Show Consistent Progression-Free Survival Benefit In Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Patients Treated With Ibrutinib, Including Those With High-Risk Disease, With Up To Four Years Of Follow-Up June 4, 2017